Hindson Benjamin J. 4

What Happened Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics (TXG), received an award of 88,816 restricted stock units (RSUs) on February 26, 2026. The RSUs were granted at $0.00 per unit (code A — award/grant), meaning this was a compensation award rather than a purchase or sale. The reported acquisition value at grant is $0.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (timely filing).
• Units granted: 88,816 RSUs; grant price reported: $0.00.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: Each RSU is a contingent right to one share of Class A common stock upon vesting. Vesting: 1/12th of the RSUs vest on each quarterly anniversary measured from February 21, 2026, subject to continued service.
• Transaction code: A = Award/Grant/Acquisition. No 10b5-1 plan, tax withholding, or sale information reported.

Context RSUs convert to actual shares only as they vest, so this grant does not represent immediate buying or selling in the market. Such awards are common as executive compensation and do not by themselves indicate insider sentiment about near-term stock moves.